Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: Pooled analyses of five double-blind, placebo-controlled trials

International Clinical Psychopharmacology

Volumn 29, Issue 4, 2014, Pages 197-205

  Sambunaris, Angelo ^a   Gommoll, Carl ^b   Chen, Changzheng ^c   Greenberg, William M ^b  

^a Atlanta Medical Research Institute   (United States)

^b Departments of Clinical Development   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

depression; disability; functional impairment; levomilnacipran extended release; major depressive disorder; Montgomery Asbergdepression rating scale; Sheehan Disability Scale

Indexed keywords

MILNACIPRAN; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE; DELAYED RELEASE FORMULATION; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; FUNCTIONAL DISEASE; HUMAN; MAJOR DEPRESSION; OUTCOMES RESEARCH; PRIORITY JOURNAL; REMISSION; SHEEHAN DISABILITY SCALE; SUSTAINED RELEASE FORMULATION; ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MONITORING; FEMALE; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84902196986     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000033     Document Type: Article

References (47)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. Fourth edition Washington, DC: American Psychiatric Association 2000; Text revision.
2. Asnis G, Bose A, Gommoll C, Chen C, Greenberg WM (2013). The efficacy and safety of levomilnacipran SR 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase III, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 74:242-248.
3. Auclair AL, Martel JC, Assie MB, Bardin L, Heusler P, Cussac D, et al. (2013). Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 70:338-347.
4. Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, et al. (2014). Levomilnacipran ER 40 mg and 80mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebocontrolled study. J Psychiatry Neurosci 39:40-49.
5. Bosworth HB, McQuoid DR, George LK, Steffens DC (2002). Time-to-remission from geriatric depression: psychosocial and clinical factors. Am J Geriatr Psychiatry 10:551-559. (Pubitemid 34984391)
6. Briley M, Moret C (2010). Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors. Neuropsychiatr Dis Treat 6:647-655.
7. CoryellW, Endicott J, Keller M (1990). Outcome of patients with chronic affective disorder: a five-year follow-up. Am J Psychiatry 147:1627-1633.
8. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL (1993). The enduring psychosocial consequences of mania and depression. Am J Psychiatry 150:720-727. (Pubitemid 23137676)
9. Esposito K, Goodnick P (2003). Predictors of response in depression. Psychiatr Clin North Am 26:353-365. (Pubitemid 36583568)
10. Gommoll C, Greenberg WM, Changzheng C (2014). A randomized double-blind, placebo-controlled, study of flexible-doses of levomilnacipran ER (40-120mg/day) in patients with major depressive disorder. J Drug Assess 3:10-19.
11. Guico-Pabia CJ, Fayyad RS, Soares CN (2011). Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis. Int Clin Psychopharmacol 27:1-7.
12. Guy W (1976). The clinician global severity and impression scales. ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health 218-222, DHEW Publication No. 76-338.
13. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
14. Hirschfeld RM, Dunner DL, Keitner G, Klein DN, Koran LM, Kornstein SG, et al. (2002). Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 51:123-133. (Pubitemid 34127902)
15. Israel JA (2006). Remission in depression: definition and initial treatment approaches. J Psychopharmacol 20:5-10. (Pubitemid 44605927)
16. Judd LL, Akiskal HS, Zeller PJ, Paulus M, Leon AC, Maser JD, et al. (2000). Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 57:375-380. (Pubitemid 30202328)
17. Judd LL, Schettler PJ, Solomon DA, Maser JD, Coryell W, Endicott J, Akiskal HS (2008). Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord 108:49-58. (Pubitemid 351418013)
18. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, Shea T (1992). Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 49:809-816.
19. Kennedy N, Foy K, Sherazi R, McDonough M, McKeon P (2007). Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord 9:25-37. (Pubitemid 46671671)
20. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105. (Pubitemid 37432885)
21. Kocsis JH (1990). New issues in the prediction of antidepressant response. Psychopharmacol Bull 26:49-53. (Pubitemid 20322244)
22. Langlieb AM, Guico-Pabia CJ (2010). Beyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry 12:e1-e14.
23. Mancini M, Sheehan DV, Demyttenaere K, Amore M, Deberdt W, Quail D, Sagman D (2012). Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan Disability Scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. Int Clin Psychopharmacol 27:298-309.
24. McKnight PE, Kashdan TB (2009). The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev 29:243-259.
25. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389. (Pubitemid 9136500)
26. Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D (2013). Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-ofconcept study. J Clin Psychiatry 74:363-369.
27. Moret C, Briley M (2011). The importance of norepinephrine in depression. Neuropsychiatr Dis Treat 7:9-13.
28. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007). Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370:851-858. (Pubitemid 47362344)
29. Murray CJ, Lopez AD (1997). Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349:1436-1442. (Pubitemid 27212192)
30. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. (2012). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197-2223.
31. Nemeroff CB (2007). The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 41:189-206. (Pubitemid 44854991)
32. Nierenberg AA (2003). Predictors of response to antidepressants general principles and clinical implications. Psychiatr Clin North Am 26:345-352 (Pubitemid 36583567)
33. Nutt DJ (2008). Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 69 (Suppl E1):4-7.
34. Sambunaris A, Bose A, Gommoll C, Chen C, Greenberg WM, Sheehan DV (2014). A Phase III double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol 34:47-56.
35. Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3):89-95. (Pubitemid 26373761)
36. Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A (2011). Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. Int Clin Psychopharmacol 26:75-83.
37. Sheehan KH, Sheehan DV (2008). Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 23:70-83. (Pubitemid 351317279)
38. Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ (2009). Assessing the efficacy of desvenlafaxine for improving functioning and wellbeing outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry 70:1365-1371.
39. Solomon DA, Leon AC, Endicott J, Mueller TI, Coryell W, Shea MT, Keller MB (2004). Psychosocial impairment and recurrence of major depression. Compr Psychiatry 45:423-430. (Pubitemid 39446806)
40. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR D: implications for clinical practice. Am J Psychiatry 163:28-40. (Pubitemid 43050100)
41. Trivedi MH (2009). Treating depression to full remission. J Clin Psychiatry 70:e01.
42. Trivedi MH, Dunner DL, Kornstein SG, Thase ME, Zajecka JM, Rothschild AJ, et al. (2010). Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord 126:420-429.
43. Vallejo J, Gasto C, Catalan R, Bulbena A, Menchon JM (1991). Predictors of antidepressant treatment outcome in melancholia: psychosocial, clinical and biological indicators. J Affect Disord 21:151-162.
44. Vittengl JR, Clark LA, Jarrett RB (2009). Deterioration in psychosocial functioning predicts relapse/recurrence after cognitive therapy for depression. J Affect Disord 112:135-143.
45. Wang PS, Simon G, Kessler RC (2003). The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 12: 22-33. (Pubitemid 36675445)
46. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. (1989). The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 262:914-919. (Pubitemid 19208948)
47. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu D (2006). How should remission from depression be defined? The depressed patients perspective. Am J Psychiatry 163: 148-150. (Pubitemid 43050117)